PTGX
$29.36
Protagonist Therapeutics
$.37
1.28%
PTGX
Earnings Whisper ®
N/A
2nd Quarter June 2023
Consensus:  ($0.65)
Revenue:  N/A
Thursday
Aug 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PTGX reports earnings?
Beat
Meet
Miss

Where is PTGX's stock price going from here?
Up
Flat
Down
Stock chart of PTGX
Analysts
Summary of analysts' recommendations for PTGX
Score
Grade
Pivots
Resistance
$30.75
$30.08
$29.72

$29.06

Support
$28.70
$28.03
$27.67
Tweet
Growth
Description
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.